Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 7, 2026Cancer Immunology Research

Abstract LB-C001: Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma: Updated Results with Over Four Years Median Follow Up

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSophie CarlsonBPBenjamin PuliafitoCWChristopher M. Walthers

Discussion

Loading...

Member takes

Overview

Phase 1 trial evaluates CART19/20 cell therapy in relapsed/refractory non-Hodgkin lymphoma, suggesting effectiveness and safety.

Key Points

  • The aim was to assess the safety and efficacy of CART19/20 cells in relapsed or refractory non-Hodgkin lymphoma.
  • Conducted a Phase 1 clinical trial with eligible patients aged 18+ and relapsed/refractory non-Hodgkin lymphoma.
  • Utilized autologous CD62L+ T cells modified with a bispecific anti-CD19/CD20 CAR through lentiviral transduction.
  • Assessed safety as the primary endpoint and clinical response, progression-free survival, and overall survival as secondary endpoints.
  • Fifteen patients received CART19/20, with a 93% overall response rate and an 80% complete response rate.
  • Median progression-free survival was 37.5 months with a mean peak cell expansion of 592,500 cells/mL.
  • Maximum cytokine release syndrome was grade 2 in one patient, along with 12 serious adverse events but no neurotoxicity.

Cite This Study

Carlson et al. (2026) studied this question.

synapsesocial.com/papers/69abc1d75af8044f7a4eadb2https://doi.org/10.1158/2326-6074.io2026-lb-c001
View Full Paper
Ask AI
Bookmark
Share